Alan G. Walton
Senior General Partner @ Oxford Bioscience Partners
Alan G. Walton is a Series F investor at Oxford Bioscience Partners focused on Health Care and Biotechnology. Alan G. Walton, Ph.D., D.Sc. has served as a director of our company since March 2003. Dr. Walton joined Oxford Partners as a General Partner in 1987. In 1991, he founded Oxford Bioscience Partners and he is currently Senior Partner and Chairman of Oxford Bioscience Corporation. Previously, he was President and CEO of University Genetics Co., apublic biotechnology company involved in technology transfer and seed investments in university-related projects. Prior to University Genetics, he taught at several institutions including Harvard Medical School, Indiana University and Case Western Reserve where he was Professor of Macromolecular Science and Director of the Laboratory for Biological Macromolecules. Dr. Walton serves on the Board of Alexandria Real Estate Equities. He is President of the National Committee on Bioscience. Dr. Walton was a founder of Human Genome Sciences, Exelixis, and GeneLogic and is the Founding Chairman of the Biotechnology Venture Investors Group. Dr. Walton holds a Ph.D. in chemistry and a D.Sc. in biological chemistry from Nottingham University in England and in 2005 received an honorary LLD degree for his lifetime achievement in life sciences from Nottingham University. Dr. Walton was elected Emeritus University Adjunct Professor at Case Western Reserve University in 2007.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Alan G. Walton invests in
Stages Alan G. Walton invests in
Countries Alan G. Walton invests in
Investment Focus
Industry
- Health Care 1 (33%)
- Biotechnology 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Series F 1 (33%)
- Post-IPO Equity 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Acadia Pharmaceuticals Inc.
|
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. TheCompany is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study. | $20M / Post-IPO Equity / Feb 07, 2006 | |
|
Acadia Pharmaceuticals Inc.
|
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. TheCompany is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study. | $10M / Post-IPO Equity / Feb 08, 2005 | |
|
Acadia Pharmaceuticals Inc.
|
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. TheCompany is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study. | $25M / Series F / Mar 31, 2003 |
Co-Investors
About Oxford Bioscience Partners
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. While willing to consider an investment in a company at almost any stage, OBP primarily works with early-stagesituations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide.
Oxford Bioscience Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alan G. Walton
Senior General Partner
|
|||
Alan Watson
Executive-in-Residence
|
|||
Julia Dan
Venture Partner
|
|||
Manuel A. Navia
Executive-in-Residence
|
|||
Paul Tu
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Alan G. Walton invest in?
Alan G. Walton invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series F and Post-IPO Equity stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alan G. Walton last invest?
The most recent investment recorded for Alan G. Walton closed in Feb 2006. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
